Kura Oncology, Inc. (NASDAQ:KURA) Receives $28.28 Average Price Target from Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have earned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $28.28.

Several research firms recently issued reports on KURA. JMP Securities boosted their price target on Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a research note on Wednesday, January 31st. Wedbush restated an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a research note on Wednesday, February 28th. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Monday, April 22nd.

Insider Activity

In related news, COO Kathleen Ford sold 1,496 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $26,628.80. Following the completion of the sale, the chief operating officer now directly owns 21,602 shares in the company, valued at approximately $384,515.60. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, COO Kathleen Ford sold 1,496 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $26,628.80. Following the completion of the sale, the chief operating officer now directly owns 21,602 shares in the company, valued at approximately $384,515.60. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Thomas James Doyle sold 2,318 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $41,260.40. Following the sale, the senior vice president now owns 48,093 shares of the company’s stock, valued at $856,055.40. The disclosure for this sale can be found here. In the last three months, insiders sold 5,867 shares of company stock worth $104,433. 5.50% of the stock is currently owned by company insiders.

Institutional Trading of Kura Oncology

Institutional investors and hedge funds have recently modified their holdings of the business. Signaturefd LLC lifted its position in shares of Kura Oncology by 40.4% during the 4th quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock worth $72,000 after buying an additional 1,449 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Kura Oncology by 352.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock worth $124,000 after purchasing an additional 6,692 shares in the last quarter. Saxon Interests Inc. acquired a new position in Kura Oncology in the 1st quarter worth about $201,000. Pale Fire Capital SE acquired a new position in Kura Oncology in the 3rd quarter worth about $92,000. Finally, E Fund Management Co. Ltd. increased its holdings in Kura Oncology by 12.2% in the 3rd quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock worth $109,000 after purchasing an additional 1,301 shares in the last quarter.

Kura Oncology Stock Performance

KURA opened at $19.65 on Wednesday. The business has a fifty day simple moving average of $20.67 and a 200 day simple moving average of $15.46. The company has a market capitalization of $1.50 billion, a PE ratio of -9.45 and a beta of 0.85. Kura Oncology has a 1 year low of $7.41 and a 1 year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.26 and a quick ratio of 12.26.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.01. During the same period in the prior year, the company earned ($0.49) earnings per share. Research analysts expect that Kura Oncology will post -2.35 EPS for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.